BOI Bank Irel13.375

RNS Number:0784W
Biotrace International PLC
17 May 2002


For Immediate Release:                                        17 May 2002


                           Biotrace International Plc

                 AGM Statement & North American Trading Update


Biotrace International Plc ('Biotrace' or the "Company"), a leading manufacturer
and distributor of industrial and medical microbiology products, held its Annual
General Meeting today at which all resolutions were duly passed.

At the meeting, Mr Terry Clements, Chairman of Biotrace, issued the following
statement:

"We are pleased to announce that following the Annual General Meeting of the
Company held this morning, all resolutions proposed were duly passed, including
a proposal to pay a maiden dividend of 0.8p per share.

At last year's AGM we announced the acquisition of Cogent Technologies 
('Cogent'), a leading supplier of instruments and reagents for sterility testing
of UHT dairy products to the North American dairy industry.  Cogent is now fully
integrated into the Company and trading is in line with our internal objectives
set last year.  As a result of the acquisition Biotrace has been able to
rationalise its North American operations in New Jersey and Cincinnati and has
created a new, larger headquarters in Cincinnati.  Also over the last year,
Cogent's sales in North America have increased by 55%, which is attributable to
Biotrace  winning contracts with further major North American dairy groups.
Cogent in Europe is also progressing well, with the European product roll out
having been successful, particularly in the UK with the winning of a further 6
major dairy groups. Cogent now holds a dominant position in the UK market.  Two
additional accounts have also been won in France, supported by our new sales
subsidiary, Biotrace SA, which commenced trading in January this year. There is
a great deal of potential business within Europe and the Americas, and Cogent is
now well positioned to achieve further growth.

We are pleased to announce today that the Company has signed a new two-year
agreement with Neogen Corporation ('Neogen') in the USA to continue to promote
the Biotrace rapid hygiene product line in North America.  Neogen, a leading US
supplier of microbiology products has been the Biotrace product line exclusive
distributor since January 2000 and has established the products as the number
one brand in North America.

Finally I am delighted to be able to announce that Biotrace was, last night,
voted Welsh Company of the Year at The Western Mail Business Awards for Wales.
This award being sponsored by the London Stock Exchange".


                                    - ENDS -



For further information, please contact:
Biotrace International
Ian Johnson, Chief Executive Officer                Tel : +44 (0) 1656 641 400
Peter Morgan, Finance Director                      Tel : +44 (0) 1656 641 400

Buchanan Communications
Nicola How                                          Tel : +44 (0)20 7466 5000



Notes to editors:

Biotrace International Plc is a leading manufacturer and supplier of rapid
microbiology instrumentation and test reagents to food, industrial, healthcare
and defence markets.  Biotrace is the acknowledged leader in rapid hygiene
testing and the continuous real-time detection of airborne biological weapons.

Many of the world's leading food manufacturers and catering companies, including
19 out of the top 20 world food groups now rely on Biotrace as an essential part
of their quality procedures. Industrial customers include many of the world's
largest water treatment chemical multi-nationals.  Biotrace also supplies highly
specialised workstations to hospitals, public health laboratories and medical
research institutes for the examination of hazardous micro-organisms and
diseases.   A significant part of the Company's business is the manufacture and
supply of equipment and reagents to the UK MoD for the detection of biological
weapons.

Formed in 1988 and floated on the London Stock Exchange in 1993, Biotrace
intends to continue to broaden its business base through organic growth and
acquisition of products and technologies to become a 'one stop shop' for its
large and growing customer base.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

Bank Irel13.375 (LSE:BOI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Bank Irel13.375 (LSE:BOI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024